The clinical efficacy and adverse effects of Entecavir plus Thymosin alpha-1 combination therapy versus Entecavir Monotherapy in HBV-related cirrhosis: a systematic review and meta-analysis

Table 2 Summary of pooled results including biochemical variables

Variable	Studies included (n)	Patients included (n)	SMD	95%CI	Significance, P	Heterogeneity
Variable	Studies included (n)	Patients included (n)	SMD	95%CI	Significance, P	P	I²
ALB
After treatment, EG vs. CG	2	90	−0.38	−2.12, 1.37	0.67	0.0001	93%
EG, before vs. after	2	90	−1.62	− 2.87, − 0.36	0.01	0.02	81%
CG, before vs. after	2	90	−1.37	−2.05, −0.68	< 0.0001	0.15	51%
AST
After treatment, EG vs. CG	4	364	−1.33	− 1.59, − 1.06	< 0.00001	0.31	14%
EG, before vs. after	4	364	8.89	3.45, 14.32	0.001	< 0.00001	99%
CG, before vs. after	4	364	7.56	2.47, 12.64	0.004	< 0.00001	99%
ALT
After treatment, EG vs. CG	6	454	−1.12	−1.70, −0.55	0.0001	< 0.00001	87%
EG, before vs. after	6	454	10.45	5.83, 15.08	< 0.00001	< 0.00001	99%
CG, before vs. after	6	454	11.61	6.69, 16.53	< 0.00001	< 0.00001	99%
TBIL
After treatment, EG vs. CG	6	454	−0..35	1.22, 0.53	0.44	< 0.00001	95%
EG, before vs. after	6	454	3.31	1.28, 5.34	0.001	< 0.00001	98%
CG, before vs. after	6	454	3.26	1.54, 4.99	0.0002	< 0.00001	97%
A/G
After treatment, EG vs. CG	3	314	0.47	−0.88, 1.82	0.49	< 0.00001	97%
EG, before vs. after	3	314	−1.26	−2.19, −0.33	0.008	< 0.00001	93%
CG, before vs. after	3	314	−1.06	−1.30, −0.83	< 0.00001	0.61	0%

CG control group, the group with ETV monotherapy, EG experimental group, the group with ETV plus Tα1 combination therapy, SMD standardized mean difference, CI confidence interval, ALT alanine aminotransferase, ALB albumin, TBIL total bilirubin; AST, aspartate aminotransferase; A/G, the albumin globulin ratio

ISSN: 1471-230X